AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37749876 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral treatment for insomnia
Number of subjects: 74
Study 37750084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vari-pad compression garment worn for 4 weeks
Number of subjects: 18
Study 37750105 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical and postsurgical nurse interventions (PROCESS-VALVE)
Number of subjects: 0
Study 37750105 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face postsurgical consultation
Number of subjects: 0
Study 37750105 — intervention group
Group type: COMPARATOR
Intervention: Telephone postsurgical consultation
Number of subjects: 0
Study 37750183 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg once daily
Number of subjects: 283
Study 37750183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 37750406 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg
Number of subjects: 207
Study 37750406 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg
Number of subjects: 207
Study 37750406 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 40 mg
Number of subjects: 207
Study 37750406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhemorrhagic stroke
Number of subjects: 21820
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure admission
Number of subjects: 21820
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident cancer
Number of subjects: 21820
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoronary revascularization
Number of subjects: 21820
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction with urgent CRV procedure
Number of subjects: 21820
Study 37750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent/nonurgent CRV procedure without myocardial infarction
Number of subjects: 21820
Study 37750558 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn device with lead-I ECG and continuous photoplethysmography (Verily Study Watch)
Number of subjects: 117
Study 37750558 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography-derived AF burden estimation
Number of subjects: 117
Study 37750558 — intervention group
Group type: COMPARATOR
Intervention: 14-day continuous ECG monitor (Zio XT)
Number of subjects: 117
Study 37750588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 128
Study 37750588 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 128
Study 37750660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential exercise-cognitive training (SEQ)
Number of subjects: 63
Study 37750660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task exercise-cognitive training (DUAL)
Number of subjects: 63
Study 37750660 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 63
Study 37750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tedizolid treatment for BJIs
Number of subjects: 44
Study 37750771 — intervention group
Group type: EXPERIMENTAL
Intervention: BPE extent quantified using fully automated software
Number of subjects: 1476
Study 37750771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiles of BPE, FGT volume, and fat volume
Number of subjects: 1476
Study 37750774 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) reconstruction of low-resolution T2-weighted turbo spin-echo (TSE) prostate MRI scans
Number of subjects: 0
Study 37750774 — intervention group
Group type: COMPARATOR
Intervention: Standard-resolution T2-weighted TSE sequence
Number of subjects: 0
Study 37750994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks, with possible uptitration to 200 or 300 mg every 2 weeks based on weight and IGA score.
Number of subjects: 321
Study 37750994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment reinitiated after stopping due to achieving clear/almost clear skin.
Number of subjects: 321
Study 37750995 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 199
Study 37751016 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin (2 × 3000 mg 10-12 h apart)
Number of subjects: 400
Study 37751016 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (500 mg, intramuscular) plus Azithromycin (1 g, oral)
Number of subjects: 400
Study 37751015 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (600 mg)
Number of subjects: 903
Study 37751015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 37751019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir + Optimized Background Therapy (OBT)
Number of subjects: 0
Study 37751022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 37751022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37751113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg twice daily)
Number of subjects: 0
Study 37751113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37751113 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study 37751153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon administration
Number of subjects: 0
Study 37751153 — intervention group
Group type: COMPARATOR
Intervention: Injectable glucagon administration
Number of subjects: 0
Study 37751186 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interaction
Number of subjects: 0
Study 37751207 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 2591
Study 37751237 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs) with notifications delivered up to 4 times per day and suggested daily step goals
Number of subjects: 48
Study 37751237 — intervention group
Group type: EXPERIMENTAL
Intervention: Notifications to walk based on JIT states considering need, opportunity, and receptivity
Number of subjects: 48
Study 37751247 — intervention group
Group type: EXPERIMENTAL
Intervention: H-Coaching programme for nurses
Number of subjects: 0
Study 37751286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Treatment (MT)
Number of subjects: 29
Study 37751286 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 29
Study 37751301 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 (GLP-1 Receptor antagonist)
Number of subjects: 2
Study 37751301 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 2
Study 37751376 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing with selective 16/18 genotyping
Number of subjects: 2409
Study 37751376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual staining cytology
Number of subjects: 2409
Study 37751429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) and patient portal
Number of subjects: 856
Study 37751429 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 856
Study 37751429 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS and patient portal
Number of subjects: 856
Study 37751455 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC algorithm for COVID-19-related admissions
Number of subjects: 1651
Study 37751455 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts classification for COVID-19-related admissions
Number of subjects: 1651
Study 37751455 — intervention group
Group type: COMPARATOR
Intervention: Patients hospitalized for COVID-19
Number of subjects: 1651
Study 37751561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg orally twice daily) and Trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks)
Number of subjects: 30
Study 37751561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib and Trastuzumab
Number of subjects: 30
Study 37751891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir 100 mg with ritonavir 100 mg administered 12 hours before, together with, and 12 and 24 hours after nirmatrelvir
Number of subjects: 16
Study 37751891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Number of subjects: 16
Study 37751948 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional radiotherapy (RT) including the axilla level I-III, supraclavicular fossa, and internal mammary nodes in selected patients. Chest-wall RT after mastectomy is given only in cases of widespread multifocality according to national guidelines.
Number of subjects: 1350
Study 37751948 — intervention group
Group type: COMPARATOR
Intervention: No regional radiotherapy (intervention arm).
Number of subjects: 1350
Study 37751948 — intervention group
Group type: COMPARATOR
Intervention: Regional RT (standard arm)
Number of subjects: 1350
Study 37751953 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 120
Study 37751961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ocular pain (36 patients, 72 eyes)
Number of subjects: 62
Study 37751961 — intervention group
Group type: COMPARATOR
Intervention: Patients without ocular pain (26 patients, 52 eyes)
Number of subjects: 62
Study 37751961 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fibre length (CNFL)
Number of subjects: 62
Study 37752337 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm dysfunction assessment on Day 1 of ECMO initiation
Number of subjects: 63
Study 37752337 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm function assessment over time
Number of subjects: 63
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DM
Number of subjects: 0
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DM-FVD
Number of subjects: 0
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedars
Number of subjects: 0
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: Emory-Votaw
Number of subjects: 0
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: Emory-Ottawa
Number of subjects: 0
Study 37752344 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartSee
Number of subjects: 0
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) before extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface available for ventilation before extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Global inhomogeneity index (GI index) after extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score (LUS) after extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface available for ventilation after extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional ventilation delay (RVD) after extubation
Number of subjects: 40
Study 37752365 — intervention group
Group type: EXPERIMENTAL
Intervention: Center of ventilation (CoV) after extubation
Number of subjects: 40
Study 37752379 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation (mild acute blood loss)
Number of subjects: 26
Study 37752423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day continuously plus lanreotide 120 mg every 28 days
Number of subjects: 69
Study 37752423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus lanreotide
Number of subjects: 69
Study 37752426 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein, omega-3 supplementation, and physical exercise program
Number of subjects: 200
Study 37752447 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week dietary intervention combined with behaviour change techniques guided by the Health Action Process Approach model
Number of subjects: 60
Study 37752447 — intervention group
Group type: COMPARATOR
Intervention: Regular health talks
Number of subjects: 60
Study 37752466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Number of subjects: 29
Study 37752466 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 29
Study 37752480 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 60
Study 37752480 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 37752531 — intervention group
Group type: EXPERIMENTAL
Intervention: Kid Gaze Rehab (KGR) combined with traditional vestibular rehabilitation
Number of subjects: 12
Study 37752564 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (remotely guided) with an educational component about cancer and exercise.
Number of subjects: 80
Study 37752566 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg/d) for 26 weeks in LiraFlame26 trial
Number of subjects: 129
Study 37752566 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg/d) for 12 weeks in LirAlbu12 trial
Number of subjects: 129
Study 37752607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning (RL) algorithm for neurostimulation parameters
Number of subjects: 54
Study 37752607 — intervention group
Group type: COMPARATOR
Intervention: Brute Force Algorithm (BFA)
Number of subjects: 54
Study 37752607 — intervention group
Group type: COMPARATOR
Intervention: Naïve approach
Number of subjects: 54
Study 37752607 — intervention group
Group type: COMPARATOR
Intervention: Trained experimenters
Number of subjects: 54
Study 37752621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 37752816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)
Number of subjects: 0
Study 37752816 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B)
Number of subjects: 0
Study 37752816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified four-drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C)
Number of subjects: 0
Study 37752878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 37752878 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 0
Study 37752882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored community communication campaigns
Number of subjects: 66
Study 37752892 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 652
Study 37752892 — intervention group
Group type: COMPARATOR
Intervention: ibrutinib
Number of subjects: 652
Study 37753225 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 4395
Study 37753225 — intervention group
Group type: COMPARATOR
Intervention: 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 4395
Study 37753336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0
Study 37753336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37753340 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified blood collection method
Number of subjects: 92
Study 37753340 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood collection method
Number of subjects: 92
Study 37753443 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette group (received a free 4-week supply of flavoured, tank-style e-cigarette)
Number of subjects: 638
Study 37753443 — intervention group
Group type: COMPARATOR
Intervention: No-product control group
Number of subjects: 638
Study 37753461 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive FDG-PET/CT response-guided radiotherapy (total dose 70-78 Gy)
Number of subjects: 20
Study 37753461 — intervention group
Group type: COMPARATOR
Intervention: Standard 70 Gy radiotherapy (control group)
Number of subjects: 20
Study 37753461 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive FDG-PET/CT response-guided radiotherapy
Number of subjects: 20
Study 37753446 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC) prescription
Number of subjects: 34421
Study 37753446 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin K antagonist oral anticoagulant (NOAC) prescription
Number of subjects: 34421
Study 37753446 — intervention group
Group type: COMPARATOR
Intervention: OAC discontinuation
Number of subjects: 34421
Study 37753446 — intervention group
Group type: COMPARATOR
Intervention: Primary composite outcome (all-cause death and major adverse cardiovascular events)
Number of subjects: 34421
Study 37753446 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolism risk
Number of subjects: 34421
Study 37753446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial haemorrhage risk
Number of subjects: 34421
Study 37753446 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding risk
Number of subjects: 34421
Study 37753640 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores and targeted proteomics added to PROMISE minimal risk score (PMRS)
Number of subjects: 1440
Study 37753640 — intervention group
Group type: COMPARATOR
Intervention: PROMISE minimal risk score (PMRS) alone
Number of subjects: 1440
Study 37753702 — intervention group
Group type: EXPERIMENTAL
Intervention: NALIRIFOX (liposomal irinotecan with 5-FU and oxaliplatin)
Number of subjects: 0
Study 37753702 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX (nonliposomal irinotecan with 5-FU and oxaliplatin)
Number of subjects: 0
Study 37753718 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray
Number of subjects: 169
Study 37753808 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT-NUDT15 gene-based dosing of 6-MP (10 to 50 mg/m2)
Number of subjects: 44
Study 37753808 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard dosing of 6-MP)
Number of subjects: 44
Study 37753954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 12
Study 37753960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd)
Number of subjects: 125
Study 37754204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 390
Study 37754204 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 390
Study 37754283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control (blood-glucose level targeted at 80 to 110 mg per deciliter)
Number of subjects: 9230
Study 37754283 — intervention group
Group type: COMPARATOR
Intervention: Liberal glucose control (insulin initiated only when blood-glucose level was >215 mg per deciliter)
Number of subjects: 9230
Study 37754283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 9230
Study 37754283 — intervention group
Group type: COMPARATOR
Intervention: Liberal glucose control
Number of subjects: 9230
Study 37754485 — intervention group
Group type: EXPERIMENTAL
Intervention: Camu camu (CC) added to nivolumab
Number of subjects: 2
Study 37754491 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation Guided Transperineal Fiducial Markers Implantation Technique
Number of subjects: 1
Study 37754571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 93797
Study 37754571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-specific mortality
Number of subjects: 93797
Study 37754571 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥60 years)
Number of subjects: 93797
Study 37754571 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 93797
Study 37754682 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal malaria exposure (PME)
Number of subjects: 0
Study 37754682 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies at birth
Number of subjects: 0
Study 37755151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) treatment, 12 sessions
Number of subjects: 34
Study 37755371 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 428
Study 37755371 — intervention group
Group type: COMPARATOR
Intervention: Nasojejunal early enteral nutrition (NJEEN)
Number of subjects: 428
Study 37755506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleach baths (0.005% NaClO; 5-10 min duration) twice a week for 12 weeks
Number of subjects: 15
Study 37755689 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI100
Number of subjects: 2701
Study 37755689 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI90 - < 100
Number of subjects: 2701
Study 37755689 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI75 - < 90
Number of subjects: 2701
Study 37755689 — intervention group
Group type: EXPERIMENTAL
Intervention: < PASI75
Number of subjects: 2701
Study 37755833 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted buprenorphine (TAB)
Number of subjects: 100
Study 37755833 — intervention group
Group type: COMPARATOR
Intervention: Control (community resource guides and assistance)
Number of subjects: 100
Study 37755958 — intervention group
Group type: COMPARATOR
Intervention: onaBoNT-A (Cohort 1)
Number of subjects: 114
Study 37755958 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT-A (Cohort 2)
Number of subjects: 114
Study 37755979 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 834
Study 37756047 — intervention group
Group type: EXPERIMENTAL
Intervention: Woebot LIFE (WB-LIFE) digital mental health intervention
Number of subjects: 255
Study 37756123 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Paliperidone Palmitate
Number of subjects: 0
Study 37756123 — intervention group
Group type: COMPARATOR
Intervention: Oral Antipsychotics
Number of subjects: 0
Study 37756299 — intervention group
Group type: COMPARATOR
Intervention: Omicron variant infection
Number of subjects: 35806
Study 37756299 — intervention group
Group type: COMPARATOR
Intervention: Wild-type/delta variant infection
Number of subjects: 35806